Abstract:Triple negative breast cancer (TNBC) has negative expression of ER, PR and HER-2. TNBC shows high histological grade and positive rate of lymph node metastasis, easy recurrence and distant metastasis. Molecular typing based on metabolic genes can reflect deeper characteristics of breast cancer and provide support for prognostic evaluation and individualized treatment. Metabolic subtypes of TNBC samples based on metabolic genes were determined by consensus clustering. CIBERSORT method was applied to evaluate the score distribution and differential expression of 22 immune cells in the TNBC samples. Linear discriminant analysis (LDA) established a subtype classification feature index. Kaplan-Meier (KM) and receiver operating characteristic (ROC) curves were generated to validate the performance of prognostic metabolic subtypes in different datasets. Finally, we used weighted correlation network analysis (WGCNA) to cluster the TCGA expression profile dataset and screen the co-expression modules of metabolic genes. Consensus clustering of the TCGA cohort/dataset obtained three metabolic subtypes (MC1, MC2, and MC3). The ROC analysis showed a high prognostic performance of the three clusters in different datasets. Specifically, MC1 had the optimal prognosis, MC3 had a poor prognosis, and the three metabolic subtypes had different prognosis. Consistently, the immune characteristic index established based on metabolic subtypes demonstrated that compared with the other two subtypes, MC1 had a higher IFNγ score, T cell lytic activity and lower angiogenesis score, T cell dysfunction and rejection score. TIDE analysis showed that MC1 patients were more likely to benefit from immunotherapy. MC1 patients were more sensitive to immune checkpoint inhibitors and traditional chemotherapy drugs Cisplatin, Paclitaxel, Embelin, and Sorafenib. Multiclass AUC based on RNASeq and GSE datasets were 0.85 and 0.85, respectively. Finally, based on co-expression network analysis, we screened 7 potential gene markers related to metabolic characteristic index, of which CLCA2, REEP6, SPDEF, and CRAT can be used to indicate breast cancer prognosis. Molecular classification related to TNBC metabolism was of great significance for comprehensive understanding of the molecular pathological characteristics of TNBC, contributing to the exploration of reliable markers for early diagnosis of TNBC and predicting metastasis and recurrence, improvement of the TNBC staging system, guiding individualized treatment.

Deep Learning Framework for Comprehensive Molecular and Prognostic Stratifications of Triple-Negative Breast Cancer

Deep Learning and Digital Pathology Power Precision Treatment of Triple-Negative Breast Cancer

Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping

Comparative Evaluation of Machine Learning Models for Subtyping Triple-Negative Breast Cancer: A Deep Learning-Based Multi-Omics Data Integration Approach

Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes

Deep Learning and Transfer Learning Identify Breast Cancer Survival Subtypes from Single-Cell Imaging Data.

Predicting Relapse in Patients With Triple Negative Breast Cancer (TNBC) Using a Deep-Learning Approach

Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning

Artificial Intelligence Learning Landscape of Triple-Negative Breast Cancer Uncovers New Opportunities for Enhancing Outcomes and Immunotherapy Responses

Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies

Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy

Deep-learning and transfer learning identify new breast cancer survival subtypes from single-cell imaging data

Molecular Characterization and Establishment of a Prognostic Model Based on Primary Immunodeficiency Features in Association with RNA Modifications in Triple-Negative Breast Cancer

Personalized chemotherapy selection for patients with triple-negative breast cancer using deep learning

Classification and Gene Selection of Triple-Negative Breast Cancer Subtype Embedding Gene Connectivity Matrix in Deep Neural Network.

Deep learning based feature-level integration of multi-omics data for breast cancer patients survival analysis

Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI

Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer

Ensemble learning-based gene signature and risk model for predicting prognosis of triple-negative breast cancer

Deep Learning-Based System for Automatic Prediction of Triple-Negative Breast Cancer from Ultrasound Images.

Progress and Challenges of Immunotherapy Predictive Biomarkers for Triple Negative Breast Cancer in the Era of Single-Cell Multi-Omics